EXHIBIT 99.1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: February 18, 2025

 

C/M Capital Master Fund, LP  
By: C/M Global GP, LLC, its General Partner  

 

By: /s/ Thomas Walsh  
  Name: Thomas Walsh  
  Title: Manager  
     

 

C/M Capital Partners, LP  

 

By: /s/ Thomas Walsh  
  Name: Thomas Walsh  
  Title: Partner  
     

 

/s/ Thomas Walsh  
 Thomas Walsh  
     
     

 

/s/ Jonathan Juchno  
Jonathan Juchno  
Biodexa Pharmaceuticals (NASDAQ:BDRX)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Biodexa Pharmaceuticals Charts.
Biodexa Pharmaceuticals (NASDAQ:BDRX)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Biodexa Pharmaceuticals Charts.